)
)
Company research20 Mar 2024
Companies That Had Their IPO in 1987: From Optimism to Black Monday
An overview of 1987's IPO landscape and stock market sentiment, as conditions turned from unabridged optimism to panic in the wake of Black Monday.
CONMED
CONMED (CNMD) investor relations material
CONMED Wells Fargo 21st Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Wells Fargo 21st Annual Healthcare Conference summary9 Sep, 2026
Growth strategy and market positioning
Focused on accelerated growth, targeting 5%-6% top-line growth in 2024 and double-digit EPS growth, with strong drivers in minimally invasive laparoscopic, robotic, and sports medicine markets.
Key products AirSeal, BioBrace, and Buffalo Filter are central to growth, delivering clinical and economic value in fast-growing markets.
Both minimally invasive surgery and sports medicine are seen as equally strong opportunities for share gain, with product growth drivers split between them.
Global demand and procedure volumes remain strong, with a shift toward ambulatory surgery centers and private hospitals outside the U.S.
The company benefits from the shift to minimally invasive procedures, aligning with its product strengths.
Financial performance and outlook
Q2 2024 organic revenue grew 6% constant currency, driven by sequential improvement in AirSeal and strong BioBrace performance.
Guidance for the second half of 2024 implies 6%-8% growth, with confidence based on commercial initiatives and international outperformance.
International business, representing 45% of sales, is expected to accelerate, aided by regulatory approvals and new product launches in markets like Brazil.
Margin expansion continues, with gross margins up 50-100 basis points and ongoing focus on free cash flow conversion and working capital improvements.
Investment in sales force and R&D will continue, balanced with margin expansion goals.
Product and geographic expansion
AirSeal shows high single-digit to low double-digit dollar growth, with clinical data supporting adoption and increased penetration in both laparoscopic and robotic procedures.
AirSeal is present in about 6%-7% of U.S. laparoscopic procedures and 35%-40% of robotic procedures, with installations expanding globally.
BioBrace benefits from strong market growth and clinical recommendations, with recent regulatory approval in Brazil and ongoing international expansion in Europe, Japan, and Canada.
Sales force expansion and training are ongoing to support product adoption and growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CONMED
- Q2 2026 delivered 6.0% organic sales growth, higher margins, and raised EPS guidance.CNMD
Q2 2026 - All proposals, including Director elections and auditor ratification, were approved by majority vote.CNMDAGM 2026
- Net income and margins rose despite a 1.3% sales drop; organic growth outlook improved.CNMDQ1 2026
- Key votes include board elections, executive pay approval, and auditor ratification.CNMDProxy filing
- 2026 guidance targets $1.345–$1.450B revenue and $4.25–$4.45 EPS, led by innovation and portfolio focus.CNMD44th Annual J.P. Morgan Healthcare Conference
- Q3 sales up 4.0%–4.3%, adjusted EPS up 16.7%, with CEO transition and hurricane impacts.CNMDQ3 2024
- Supply chain recovery, strong AirSeal performance, and margin growth drive a positive outlook.CNMD2024 Wells Fargo Healthcare Conference
- Q2 sales and margins improved, but full-year guidance was reduced amid supply chain delays.CNMDQ2 2024
- 2025 guidance targets 4–6% revenue growth and $4.25–$4.40 adjusted EPS, with supply chain and currency headwinds.CNMDQ4 2024
Next CONMED earnings date
Q3 202628 Oct, 2026
CONMED
Next CONMED earnings date
Q3 202628 Oct, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CONMED Corporation develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, such as powered surgical instruments for use in arthroscopic and reconstructive orthopedic surgeries; sports medicine products; electrosurgical products that include generators, electrodes, and accessories; video equipment to facilitate visualization of the surgical field during minimally invasive procedures; and disposable fluid management systems to support various surgical procedures.